Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
| Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
| Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
| Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
| Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
| Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn |
Last Updated : April 27, 2024